Since evidence-based medicine has been pursued in complementary and alternative medicine, the clinical practice guideline (CPG) has become a key factor in providing standardized and validated practices in Korean Medicine (KM). We aimed to review the current status and characteristics of the development, dissemination, and implementation of KM-CPGs. We searched KM-CPGs and relevant publication via web-based databases. We organized the searching results focused on the year of publications and the development programs to show which and how KM-CPGs have been development. We also reviewed the manuals for KM-CPG development to introduce concise characteristics of the KM-CPGs published in Korea. The KM-CPGs have been developed according to manuals and standard templates for developing evidence-based KM-CPGs. First, CPG developers reviews the previously published CPGs for a clinical condition of interest and plans the CPG development. After finalizing the key clinical questions, the evidence is searched, selected, appraised, and analyzed following the internationally standardized methods. The quality of the KM-CPGs is controlled by a tri-step appraisal process. Second, the CPGs were submitted for the appraisal of the KM-CPG Review and Evaluation Committee. The committee evaluates the CPGs according to the AGREE II tool. Finally, the Steering Committee of the KoMIT project reviews the entire process of developing the CPGs and confirms it for public disclosure and dissemination. Evidence-based KM from research to practice can be achieved with the attention and effort of multidisciplinary entities such as clinicians, practitioners, researchers, and policymakers for the CPGs.
Herbal medicine decoctions (HMD) are potential treatments for Bell’s palsy (BP), but real-world evidence regarding the safety is limited. This study investigated whether HMD use for BP was associated with risk of adverse events using a nationwide claims-based database in South Korea. This retrospective cohort study used data from the Korean Health Insurance Review and Assessment database. We applied coarsened exact matching, through which 1627 BP patients who received at least one HMD prescription between November 2020 and February 2022 were matched with 1627 BP patients who did not use HMD. Difference-in-differences logistic regression modeling compared the incidences of safety outcomes between HMD users and non-users. No significant differences were observed in the risk of hepatotoxicity, renal failure, allergic events, hospitalization, and emergency department visits between HMD users and non-users with BP, assessed at 3, 6, 9 and 11 months after HMD prescription. All effect estimates and corresponding 95 % confidence intervals included the null value. There was no significant difference in the risk of safety outcomes between HMD users and non-users with BP. Further research is warranted to understand the safety of specific herbal formulas or individual herbs using broader safety measures.